Gentile Kimberly
Known title: SVP, Clinical OperationsCIK: 0001704186
Associated companies
Transaction History
| BHVN | ▲ Buy | Option Exercise | 3,750 | $0 | 1/5/2026 | View on chart |
| BHVN | ▼ Sell | Tax Withholding | 1,956 | $19K | 1/5/2026 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 3,750 | $0 | 1/5/2025 | View on chart |
| BHVN | ▼ Sell | Tax Withholding | 1,956 | $76K | 1/5/2025 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 387 | $2K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 13,801 | $57K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 14,000 | $40K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 30,958 | $50K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 1,542 | $2K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 295 | $304 | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 20,716 | $21K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 3,000 | $8K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 12,612 | $80K | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Other | 5,826 | $0 | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Other | 1,875 | $0 | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Other | 6,500 | $0 | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 1,199 | $5K | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Other | 3,750 | $0 | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 4,500 | $8K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 12,500 | $7K | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Tax Withholding | 37,492 | $262K | 10/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Biohaven signs $100M deal with Ono for IgG degraders
Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.
Biohaven signs $100M deal with Ono for IgG degraders. Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.